IL-4/IL-13/TSLP

Class

Once-monthly trispecific antibody targeting IL-4, IL-13, and TSLP

IL-4, IL-13, and TSLP (thymic stromal lymphopoietin) are signaling proteins central to type 2 inflammation, the immune pattern implicated in asthma, atopic dermatitis, and related allergic conditions. IL-4 and IL-13 act downstream, driving immunoglobulin E production, mucus secretion, and recruitment of eosinophils, cells that contribute to tissue damage in allergic disease. TSLP acts further upstream: it is released by epithelial cells lining the airway or skin in response to irritants, allergens, or infection, and it activates dendritic cells and innate lymphoid cells that set the type 2 cascade in motion. A single molecule engineered to bind all three targets is designed to interrupt this pathway at two points rather than one - blocking the initiating epithelial signal (TSLP) as well as the effector cytokines that carry out much of the downstream tissue inflammation (IL-4/IL-13). The rationale is that patients whose disease is driven predominantly by the upstream alarmin, by the downstream effectors, or by both, could respond to a single agent, potentially offering broader or more complete suppression of type 2 inflammation than an antibody restricted to one node. This approach is relevant across chronic inflammatory diseases of the airway, skin, and sinonasal tissue where type 2 signaling is a major driver.